Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of OP0595 (Nacubactam) in Healthy Males
NCT02134834Phase 1Completed
- Sponsor
- Meiji Seika Pharma Co., Ltd.
- Start
- May 2014
- Primary completion
- Aug 2014
- Modality
- Multivalent & Scaffold-Based Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Nacubactam in bacterial infection (2 arms), sponsored by Meiji Seika Pharma Co., Ltd. Primary endpoint: Safety from baseline through the end of the study. Started May 2014; status: completed.
02
Drugs
Nacubactam
03
Conditions
bacterial infection
Beyond the preview
Go deeper on NCT02134834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02134834.